[HTML][HTML] Heparin therapy improving hypoxia in COVID-19 patients–a case series

EM Negri, BM Piloto, LK Morinaga, CVP Jardim… - Frontiers in …, 2020 - frontiersin.org
Introduction Elevated D-dimer is a predictor of severity and mortality in COVID-19 patients,
and heparin use during in-hospital stay has been associated with decreased mortality. COVID…

[HTML][HTML] Skeletal muscle abnormalities in pulmonary arterial hypertension

…, AL Pereira de Albuquerque, C Jardim, LK Morinaga… - PLoS …, 2014 - journals.plos.org
Background Pulmonary arterial hypertension is a progressive disease that is characterized
by dyspnea and exercise intolerance. Impairment in skeletal muscle has recently been …

Schistosomiasis and pulmonary hypertension

…, A Hovnanian, S Hoette, LK Morinaga… - Expert review of …, 2011 - Taylor & Francis
Schistosomiasis is one of the most prevalent chronic infectious diseases in the world. One of
its most severe complications, pulmonary hypertension, occurs in up to 5% of patients with …

[HTML][HTML] New anticoagulants for the treatment of venous thromboembolism

…, F Gavilanes, LF Prada, LK Morinaga… - Jornal Brasileiro de …, 2016 - SciELO Brasil
Worldwide, venous thromboembolism (VTE) is among the leading causes of death from
cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum …

[HTML][HTML] Update on the treatment of pulmonary arterial hypertension

…, W Salibe-Filho, LT Kato-Morinaga… - Arquivos brasileiros de …, 2021 - SciELO Brasil
In the last decades, important advances have been made in the treatment of pulmonary
arterial hypertension (PAH), a severe, progressive, incurable, and potentially fatal disease. For …

[HTML][HTML] Lung cavities in chronic thromboembolic pulmonary hypertension

…, M Terra-Filho, CVP Jardim, LT Kato-Morinaga… - Clinics, 2020 - SciELO Brasil
OBJECTIVES: Chronic thromboembolic pulmonary hypertension (CTEPH) is a unique form
of pulmonary hypertension (PH) that arises from obstruction of the pulmonary vessels by …

[HTML][HTML] Os novos anticoagulantes no tratamento do tromboembolismo venoso

…, F Gavilanes, LF Prada, LK Morinaga… - Jornal Brasileiro de …, 2016 - SciELO Brasil
Worldwide, venous thromboembolism (VTE) is among the leading causes of death from
cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum …

Pulmonary arterial hypertension in the southern hemisphere

…, C Jardim, CJC dos Santos Fernandes, LTK Morinaga… - Chest, 2015 - Elsevier
BACKGROUND Pulmonary arterial hypertension (PAH) is a rare and ultimately fatal disorder
of the pulmonary vasculature. There is increasing interest in the worldwide characteristics …

Schistosomiasis and pulmonary hypertension

…, A Hovnanian, S Hoette, LK Morinaga… - Pulmonary Vascular …, 2012 - karger.com
Schistosomiasis is the third leading parasitic disease in the world. It is present in 74 countries,
infecting 200 million people. Each year 280,000 patients die because of the disease. One …

Platelets and chronic thromboembolic pulmonary hypertension

T Oliveira, L Kato-Morinaga, A Assad, E Oliveira… - 2019 - Eur Respiratory Soc
Chronic thromboembolic pulmonary hypertension (CTEPH) is one of the most relevant forms
of pulmonary hypertension (PH). While platelet role in the acute thrombosis and pulmonary …